Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression

Abstract

Objective

The objective of this study is to evaluate the efficacy of a tightly controlled renoprotective protocol in systemic lupus erythematosus (SLE) patients with persistent proteinuria.

Methods

Thirteen SLE patients with nephritis and persistent proteinuria (>1 g/24 hours) were included. The protocol consisted of regular clinical evaluations every two weeks to assess blood pressure (BP, target <130/80 mmHg), adherence to therapy, diet and smoking. No change in immunosuppressive drugs was allowed but reduction of glucocorticoid dose was permitted if indicated. Clinical, laboratory and treatment evaluations were performed at baseline and at the end of the study (after three months).

Results

SLE patients had a mean age of 37.85 ± 7.68 years and disease duration of 9.85 ± 7.29 years. At baseline, patients had a mean duration of maintenance therapy of 10.38 ± 7.56 months, 12 with mycophenolate mofetil (92.3%) and one with azathioprine (7.7%). At least one dose optimization of antihypertensive regimen was required in all patients during the study. Seven patients (53.8%) had BP>130/80mmHg at baseline. At the end, 11 patients (84.6%) achieved stable BP target; 92.3% were using an angiotensin-converting enzyme inhibitor, 53.9% an angiotensin receptor blocker, and 46.2% were using combined therapy. All patients had a significant reduction in proteinuria levels (2.26 ± 1.09 vs 0.88 ± 0.54 g/24 hours, p < 0.001) and 61.5% achieved proteinuria <1 g/24 hours. A significant decrease in mean prednisone dose was observed (10.96 ± 6.73 vs 5.38 ± 3.36 mg/day, p = 0.013) as well as mean Systemic Lupus Erythematosus Disease Activity Index score (4.38 ± 0.72 vs 3.08 ± 1.86, p = 0.043). No significant changes were identified in serum creatinine, albumin, potassium, complement 3 and complement 4 levels (p > 0.05).

Conclusion

This study provides evidence that a tightly controlled renoprotective protocol is effective in reducing persistent proteinuria in lupus nephritis. The concomitant reduction of prednisone without any change in immunosuppression reinforces the importance of strategies beyond the treatment of nephritis activity.

Keywords

Nephritis proteinuria renoprotective strategies systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Bertsias

Tektonidou

Amoura

et al.

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771–1782.

Griffin

Lightstone

. Renoprotective strategies in lupus nephritis: Beyond immunosuppression. Lupus 2013; 22: 1267–1273.

Cravedi

Ruggenenti

Remuzzi

. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012; 8: 301–306.

Imai

Haneda

Chan

et al.

Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: A post hoc analysis (ORIENT-proteinuria). Nephrol Dial Transplant 2013; 28: 2526–2534.

Ruggenenti

Perna

Remuzzi

. GISEN Group Investigators. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254–2261.

Dall’Era

Cisternas

Smilek

et al.

Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015; 67: 1305–1313.

Tamirou

D’Cruz

Sangle

et al.

Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016; 75: 526–531.

Ugolini-Lopes

Seguro

LPC

Castro

MXF

et al.

Early proteinuria response: A valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?

Lupus Sci Med 2017; 4: e000213–e000213.

Tan

Cohen

Fries

et al.

The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

10.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

11.

Hahn

McMahon

Wilkinson

et al.

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797–808.

12.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Inter Suppl 2012; 2: 337–414.

13.

Wheeler

Becker

. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 2013; 83: 377–383.

14.

Jafar

Stark

Schmid

et al.

Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003; 139: 244–252.

15.

Abbate

Zoja

Remuzzi

. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974–2984.

16.

Gentile

Remuzzi

Ruggenenti

. Dual renin-angiotensin system blockade for nephroprotection: Still under scrutiny. Nephron 2015; 129: 39–41.

17.

Costedoat-Chalumeau

Pouchot

Guettrot-Imbert

et al.

Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013; 27: 329–340.

18.

Marengo

Waimann

de Achaval

et al.

Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus 2012; 21: 1158–1165.

19.

Barr

Magder

Petri

. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2350–2357.

20.

Petri

van Vollenhoven

Buyon

et al.

Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65: 2143–2153.